ЛИТЕРАТУРА
1. Делекторская В.В., Кушлинский Н.Е. Нейроэндокринные опухоли пищеварительной системы: морфологический спектр и клеточная пролиферация (индекс Ki-67) // Вестник РАМН. 2013. № 5. С. 1-10.
2. Горбунова В.А., Егоров А.В., Кочатков А.В. Нейроэндокринные опухоли желудочно-кишечного тракта. Принципы диагностики и лечения : руководство для врачей. Москва, 2009. 196 с.
3. Горбунова В.А. Нейроэндокринные опухоли: актуальные изменения в классификации, диагностике и терапии, представленные в проекте клинических рекомендаций МЗ РФ 2019 г // Фарматека. 2019. Т. 26, № 12. С. 8-14.
4. Гуревич Л.Е., Казанцева И.А., Калинин А.П. и др. Морфологические критерии злокачественности нейроэндокринных опухолей поджелудочной железы (30-летний опыт) // Анналы хирургии. 2007. № 3. С. 41-46.
5. Гуревич Л.Е., Корсакова Н.А., Воронкова И.А. и др. Иммуногистохимическое определение экспрессии рецепторов к соматостатину 1, 2А, 3 и 5 типа в нейро- эндокринных опухолях различной локализации и степени злокачественности // Альманах клинической медицины. 2016. Т. 44, № 3. С. 378-390.
6. Гуревич Л.Е., Казанцева И.А. Современные подходы к морфологической диагностике нейроэндокринных опухолей поджелудочной железы и прогнозированию их клинического течения на основе анализа собственной базы данных // Альманах клинической медицины. 2018. Т. 46, № 4. С. 298-313.
7. Гуревич Л.Е., Прощина А.Е., Воронкова И.А. и др. Дифференциально-диагно- стическое значение экспрессии транскрипционного фактора PDX-1 в нейроэн- докринных и не-нейроэндокринных опухолях поджелудочной железы и других органов // Архив патологии. 2019. Т. 81, № 5. С. 11-21.
8. Гуревич Л.Е., Воронкова И.А., Марова Е И. и др. Клинико-морфологическая характеристика АКТГ-секретирующих опухолей различной локализации с экто- пическим синдромом Кушинга // Альманах клинической медицины. 2017. Т. 45 , № 4. С. 289-301.
9. Егоров А.В., Кондрашин С.А., Фоминых Е.В. и др. Аналоги соматостатина в диагностике и лечении нейроэндокринных опухолей // Анналы хирургической гепатологии. 2010. Т. 14. № 4. С. 1-7.
10. Кузин Н.М., Егоров А.В. Нейроэндокринные опухоли поджелудочной железы. Москва : Медицина, 2001.
11. Майстренко Н.А., Ромащенко П.Н., Орлова Р.В., Люсанюк М.В. Возможности лечения больных с генерализованными нейроэндокринными опухолями // Онкология: журнал имени П.А. Герцена. 2018. № 2. С. 15-25.
12. Нейроэндокринные опухоли желудочно-кишечного тракта. Принципы диагностики и лечения : руководство для врачей / под ред. В.А. Горбуновой, А.В. Егорова, А.В. Кочаткова. Москва, 2009.
13. Нейроэндокринные опухоли : руководство для врачей / под ред. M. Caplin, L. Kvois. Москва : Практическая медицина, 2010.
14. Черноусов А.Ф., Егоров А.В., Мусаев Г.Х. и др. Нейроэндокринные опухоли поджелудочной железы: 30-летний опыт клиники факультетской хирургии им. Н.Н. Бурденко // Хирургия. 2013. № 7. С. 13-19.
15. Agaimy A., Erlenbach-Wunsch K., Konukiewitz B. et al. ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin // Mod. Pathol. 2013. Vol. 26. P. 995-1003.
16. Albores-Saavedera J., Batich K., Hossai S. et al. Carcinoid tumors and small-cell carcinoma of the gallbladder and extrahepatic bile duct: a comparative study based on 221 cases from the Surveillance, Epidemiology and Results Program // Ann. Diagn. Pathol. 2009. Vol. 13, N 6: 378-383.
17. Albores-Saavedera J., Hart A., Chable-Montero F., Henson D.E. Carcinoid and highgrade neuroendocrine carcinomas of the Ampulla of Vater: a comparative analyses of 139 cases from the Surveillance, Epidemiology And Results program population based study // Arch. Pathol. Lab. Med. 2010. Vol. 134, N 11. P. 1692-1696.
18. Alexandraki K.I., Grossman A.B. The ectopic ACTH syndrome // Rev. Endocr. Metab. Disord. 2010. Vol. 11, N 2. P. 117-126.
19. Akiyama T., Shada T., Yoshitomi H. et al. Expression of sex determining region Y-box 2 and pancreatic and duodenal homeobox 1 in pancreatic neuroendocrine tumors // Pancreas. 2016. Vol. 45, N 4. P. 522-527.
20. Anlauf M., Garberger N., Henopp T. et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features // World J. Gastroeterol. 2006. Vol. 12, N 34. P. 5440-5446.
21. Andersson E.S., Arvidsson Y., Sward C. et al. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets // Mod. Pathol. 2016. Vol. 29, N 6. P. 616-629.
22. Andersson E.S., Sward C., Srenman G. et al. High-resolution genomic profiling reveals gain of chromosome 14 as predictor of poor outcome in ileal carcinoids // Endocr. Relat. Cancer. 2009. Vol. 16, N 3. P. 953-966.
23. Bartsch D.K., Slater EP., Albers M. et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain // J. Clin. Endocrinol. Metab. 2014. Vol. 99, N 11. P. E2387-E2391.
24. Bartsch D.K., Waldmann J., Fendrich V. et al. A impact of lymphadenectomy of survival after surgery for sporadic gastrinoma // Br. J. Surg. 2012. Vol. 99, N 9. P. 1234-1240.
25. Basturk O., Yang Z., Tang L.H. et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms // Am. J. Surg. Pathol. 2015. Vol. 39, N 5. P. 683-690.
26. Basturk O., Tang L.H., Hruban R.H. et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: clinicopathologic analyses of 44 cases // Am. J. Surg. Pathol. 2014. Vol. 38, N 4. P. 437-447.
27. Bellizzi A.M. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry // Adv. Anat. Pathol. 2013. Vol. 20. P. 285-314.
28. Bergmann F., Breinig M., Hopfner M. et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? // Am. J. Gastroenterol. 2009. Vol. 104, N 1. P. 171-181.
29. Berna M.J., Annabale B., Marignani M. et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellson syndrome: identification of risk factors // J. Clin. Endocrinol. Metab. 2008. 93, N 5. P. 1582-1591.
30. Bordi C. Neuroendocrine pathology of the stomach: the Parma contribution // Endocr. Pathol. 2014. Vol. 25, N 2. P. 171-180.
31. Brenner B., Shah M.A., Gonen M. et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases // Br. J. Cancer. 2004. Vol. 90. P. 1720-1726.
32. Burke A.P., Thomas R.M., Elsayed E.M. et al. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases // Cancer. 1997. Vol. 79, N 6. P. 1086-1093.
33. Cao Y., Gao Z., Li L. et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1 // Nat. Commun. 2013. Vol. 4. P. 2810.
34. Capelli P., Martignoni G., Pedica F. et al. Endocrine neoplasms of the pancreas. Pathologic and genetic features // Arch. Pathol. Lab. Med. 2009. Vol. 133. P. 350-364.
35. Carrera C., Kunk P., Rahma O. Small cell carcinoma of gallbladder: case report and comprehensive analyses of published cases // J. Oncol. 2015. Vol. 2015. Article ID 304909.
36. Cen D., Chen J., Li Z., Zhao J., Cai X. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrinetumor: a meta-analysis // PLoS One. 2017. Vol. 12, N 11. Article ID e0187588.
37. Chan E.S., Alexander J., Swanson P.E. et al. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunochemical panel for pancreatic neuroendocrine neoplasms // Am. J. Pathol. 2012. Vol. 36. P. 737-743.
38. Chen C., Wang L., Liu X. et al. Galbladder neuroendocrine carcinomas: report of cases and comparison clinicopahological features with gallbladder adenocarcinoma // J. Clin. Exp. Pathol. 2015. Vol. 8, N 7. P. 82-88.
39. Choi A.B., Maxwell J.E., Keck K.L. et al. Is multifocaility an indicator of aggressive behavior in small bowel neuroendocrine tumors? // Pancreas. 2017. Vol. 46, N 9. P. 1115-1120.
40. Chopin-Laly X., Walter T., Hervieu V. et al. Neuroendocrine neoplasms of the jejunum: a heterogeneous group with distinctive proximal and distal subsets // Virchows Arch. 2013. Vol. 462, N 5. P. 489-499.
41. Chu Q.D., Hill H.C., Douglass H.O. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas // Ann. Surg. Oncol. 2002. Vol. 9, N 9. P. 855-862.
42. Couvelard A., Deschamps L., Ravaud P. et al. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors // Mod. Pathol. 2009. Vol. 22. P. 273-281.
43. Cunningham J.L., Grimelius L., Sundin A. et al. Malignant ileocaecal serotoninproducing carcinoid tumours: the presence of solid growth pattern and/or Ki-67 index above 1% identifies patients with a poorer prognosis // Acta Oncol. 2007. Vol. 46, N 6. P. 747-756.
44. Dasari A., Shen C., Halperin D. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States // JAMA Oncol. 2017. Vol. 3, N 10. P. 1335-1342.
45. Delle Fave G., O Tool D., Sundin A. et al. ENETS consensus guideline update for gastroduodenal neuroendocrine neoplasms // Neuroendocrinology. 2016. Vol. 193, N 2. P. 119-124.
46. De Wilde R.F., Heaphy C.M., Maitra A. et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors // Mod. Pathol. 2012. Vol. 25. P. 1033-1039.
47. Deschamps L., Couvelard A. Endocrine tumors of the appendix. A pathologic review // Arch. Pathol. Lab. Med. 2010. Vol. 134. P. 871-875.
48. Dhall D., Martens R., Bresee C. et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors // Hum. Pathol. 2011. Vol. 5. P. 1-7.
49. Dieckhoff P., Runkel H., Daniel H. et al. Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections // Digestion. 2014. Vol. 90, N 20. P. 89-97.
50. Doi M., Imai T., Shichiri M. et al. Octreotide-sensitive ectopic ACTH production by islet-cell carcinoma with multiple liver metastases // Endocr. J. 2003. Vol. 50, N 2. P. 135-143.
51. Donow C., Pipeleers-Marichal M., Schroder S. et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy // Cancer. 1991. Vol. 68, N 6. P. 1329-1334.
52. Esposito I., Segler A., Steiger K. et al. Pathology, genetics and precursors of human and experimental pancreatic neoplasms: an update // Pancreatology. 2015. Vol. 15, N 6. P. 598-610.
53. Estrozi B., Bacchi C.E. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation 773 cases // Clinics (Sao Paolo). 2011. Vol. 66, N 10. P. 1671-1675.
54. Falconi M., Eriksson B., Kalsas G. et al. ENETS Consensus guidelines update for the management of patients with functional pancreatic tumors and non-functional pancreatic neuroendocrine tumors // Neuroendocrinology. 2016. Vol. 103, N 2. P. 153-171.
55. Ferrone C.R., Tang L.H., Tomlinson J. et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? // J. Clin. Oncol. 2007. Vol. 25, N 35. P. 5609-5615.
56. Fischer T., Doll C., Jacobs S. et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1 // J. Clin. Endocrinol. Metab. 2008. Vol. 93. P. 4519-4524.
57. Franco J., Feng W., Yip L. et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology and outcomes in 2 158 patients // J. Gastrointest. Surg. 2010. Vol. 14, N 3. P. 541-548.
58. Fujino K., Yasufuku K., Kudoh S. et al. INSM1 is the best marker for the diagnosis of neuroendocrine tumors: comparison with CGA, SYP and CD56 // Int. J. Clin. Exp. Pathol. 2017. Vol. 10, N 5. P. 5393-5405.
59. Furlan D., Cerutti R., Genasetti A. et al. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut // Lab. Invest. 2003. Vol. 83, N 7. P. 963-971.
60. Halfdanarson T.R., Rabe K.S., Robin J. et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival // Ann. Oncol. 2008. Vol. 19, N 10. P. 1727-1733.
61. Hamilton S.R., Liu T.C., Cavatiao A. et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms // Surgery. 2012. Vol. 151, N 1. P. 107-113.
62. Hauso O., Gustafsson B.I., Kidd M. et al. Neuroendocrine tumor epidemiology: contrasting Norwey and North America // Cancer. 2008. Vol. 113, N 10. P. 2655-2664.
63. Heetfeld M., Chougnet C.N., Olsen I.H. et al. Characteristic and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms // Endocr. Relat. Cancer. 2015. Vol. 22, N 4. P. 657-664.
64. Henderson L., Fehily C., Folaranmi S. et al. Management and outcome of neuroendocrine tumors of the appendix - a two center UK experience // J. Pediatr. Surg. 2014. Vol. 49, N 10. P. 1513-1517.
65. Hermann G., Konukiewitz B., Schmitt A. et al. Hormonally defined pancreatic and uodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2 // Virchows Arch. 2011. Vol. 459. P. 147-154.
66. Hosomura K., Sato K., Honma M. et al. Small-cell carcinoma of the extrahepatic bile duct: a case report and review of the literature // Hepatol. Int. 2008. Vol. 2, N 1. P. 129-132.
67. Huang Q., Wu H., Nie L. et al. Primary high-grade neuroendocrine carcinoma of the esophagus. A clinicopathologic and immunohistochemical study of 42 resection cases // Am. J. Surg. Pathol. 2013. Vol. 37. P. 467-483.
68. Garbrecht N., Anlauf M., Schmmit A. et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity // Endocr. Relat. Cancer. 2008. Vol. 15, N 1. P. 229-241.
69. Geller S.A., Dhall D., Alsabeh R. Application of immunohistochemistry to liver and gastrointestinal neoplasms. Liver, stomach, colon, pancreas // Arch. Pathol. Lab. Med. 2008. Vol. 132. P. 490-499.
70. Ghaferi A.A., Chojnacki K.A., Long W.D. et al. Pancreatic VIPovas: subject review and one institutional experience // J. Gastrointest. Surg. 2008. Vol. 12, N 2. P. 382-393.
71. Glazer E.S., Tseng J.F., Al-Refaie W. et al. Long-term survival after surgical management of neuroendocrine hepatic metastases // HPB (Oxford). 2010. Vol. 12, N 6. P. 427-433.
72. Gleen S.T., Jones C.A., Sexton S. et al. Conditional deletion of p53 and RB1 in the renin-expressing compartment of the pancreatic neuroendocrine tumors // Oncogene. 2014. Vol. 33, N 50. P. 5706-5715.
73. Graham R.P., Shrestha B., Caron B. et al. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases // Am. J. Surg. Pathol. 2013. Vol. 37. P. 399-405.
74. Guillermet-Guibert J. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects // Best Pract. Res. Clin. Gastroenterol. 2005. Vol. 19, N 4. P. 535-551.
75. Gurevich L., Kazantseva I., Isakov V. et al. The analysis of immunophenotype of gastrin-producing tumors of pancreas and gastrointestinal tract // Cancer. 2003. Vol. 98, N 9. P. 1967-1976.
76. Jaffee I.M., Rahmani M., Singhal M.G. et al. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin // Arch. Pathol. Lab. Med. 2006. Vol. 130. P. 1522-1526.
77. Jain R., Fischer S., Serra S., Chetty R. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver // Appl. Immunohistochem. Mol. Morphol. 2010. Vol. 18, N 1. P. 9-15.
78. Jiao Y., Shi C., Edil B.H. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors // Science. 2011. Vol. 331, N 6021. P. 1199-1203.
79. Jamali M., Chetty R. Predicting prognosis in gastroenteropancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining // Endocr. Pathol. 2008. Vol. 19. P. 282-288.
80. Jensen R.T., Cadiot G., Brandi M.L. et al. NETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine syndromes // Neuroendocrinology. 2012. Vol. 95, N 2. P. 98-119.
81. Ito T., Igarashi H., Nakamura K. et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis // J. Gastrointerol. 2015. Vol. 50, N 1. P. 58-614.
82. Kamboj M., Gandgi J.S., Gupta G. et al. Neuroendocrine carcinoma of Gallbladder: a series of 19 cases with review literature // J. Gasrointest. Cancer. 2015. Vol. 46, N 4. P. 356-364.
83. Kanetkar A.V., Patkar S., Khrobragade K.H. et al. Neuroendocrine carcinoma of the gallbladder: a step beyong palliative therapy, experience of 25 cases // J. Gastrointest. Cancer. 2019. Vol. 50, N 2. P. 298-303.
84. Kaulgen X.M., Nilubol N., Kebebew E. et al. Malignant-functioning neuroendocrine tumors of the pancreas: a survival analyses // Surgery. 2016. Vol. 159, N 6. P. 1382-1389.
85. Kim J.Y., Kim M.-S., Kim K.S. et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors // Am. J. Surg. Pathol. 2015. Vol. 39. P. 592-601.
86. Kim K.M., Kim M.J., Cho B.K. et al. Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas // Virchows Arch. 2002. Vol. 440, N 1. P. 85-93.
87. Kim J.Y., Kim M.S., Kim K.S. et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors // Am. J. Surg. Pathol. 2015. Vol. 39, N 5. P. 592-601.
88. Klimstra D.S., Pitman M.B., Hruban R.H. An algorithmic approach to the diagnosis of pancreatic neoplasms // Arch. Pathol. Lab. Med. 2009. Vol. 133. P. 454-464.
89. Klimstra D.S., Modlin I.R., Adsay N.V. et al. Pathology reporting of neuroendocrine tumours: application of the Delphic consensus process to the development of minimum pathology data sate // J. Surg. Pathol. 2010. Vol. 34, N 3. P. 300-313.
90. Konukiewitz B., Enosawa T., Klöppel G. et al. Glucagon expression in cystic pancreatic Neuroendocrine neoplasms: immunohistochemical analysis // Virchows Arch. 2011. Vol. 458, N 1. P. 47-53.
91. Konukiewitz B., Schlitter A.M., Jesinghaus M. et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki-67-index above 20% // Mod. Pathol. 2017. Vol. 30, N 4. P. 587-598.
92. Konukiewitz B., Jesinghaus M., Steiger K. et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3 // Hum. Pahol. 2018. Vol. 77. P. 70-79.
93. Koo J., Mertens R.B, Mirocha J.M. et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin // Mod. Pathol. 2012. Vol. 25. P. 893-901.
94. Krejs G.J. VIPoma syndrome // Am. J. Med. 1987. Vol. 82, N 5B. P. 37-58.
95. Kulke M.N., Anthony L.B., Bushnell D.L. et al. NANETS treatment guidelines: welldifferentiated neuroendocrine tumors of the stomach and pancreas // Pancreas. 2010. Vol. 39, N 6. P. 735-752.
96. La Rosa S., Klersy C., Usella S. et al. Improved histologic and clinicophatologic criteria for prognostic evaluation of pancreatic neuroendocrine tumors // Hum. Pathol. 2009. Vol. 40. P. 30-40.
97. La Rosa S., Inzani F., Vanoli A. et al. Histological characterization and improved prognostic evalution of 209 gastric neuroendocrine neoplasms // Hum. Pathol. 2011. Vol. 42, N 10. P. 1373-1384.
98. La Rosa S., Franzi F., Albarello L. et al. Serotonin producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors // Pancreas. 2011. Vol. 40, N 6. P. 883-895.
99. La Rosa S., Adsay V., Albarello L. et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into of the morphology and search for prognostic markers // Am. J. Surg. Pathol. 2012. Vol. 36, N 12. P. 1782-1795.
100. La Rosa S., Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions // J. Clin. Pathol. 2014. Vol. 67, N 11. P. 938-948.
101. Lawrence B., Gustafsson B.I., Chan A. et al. The epidemiology of gastroenteroenteropancreatic neuroendocrine tumors // Endocrinol. Metab. Clin. North Am. 2011. Vol. 40, N 1. P. 1-18.
102. Le Roux C., Lombard-Bohas C., Deimas C. et al. Relapse factors for ileal neuroendocrine tumours after curative surgery: retrospective French multicenter study // Dig. Liver Dis. 2011. Vol. 43, N 10. P. 828-833.
103. Lee M., Pellegata N.S. Multiple endocrine neoplasia syndrome associated with mutation p27 // J. Endocrinol. Invest. 2013. Vol. 36, N 9. P. 781-787.
104. Leoncini E., Carioli G., La Vacchia C. et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analyses // Ann. Oncol. 2016. Vol. 27, N 1. P. 68-81.
105. Leoncini E., Boffetta P., Safir M. et al. Increased incidence trend of low-grade and highgrade neuroendocrine neoplasms // Endocrine. 2017. Vol. 58, N 2. P. 368-379.
106. Lichtenauer U.D., Di Dalmazi G., Slater E.P. et al. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas // J. Clin. Endocrinol. Metab. 2015. Vol. 100, N 5. P. E776-E782.
107. Ma J., Chen M., Wang J. et al. Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer // Carcinogenesis. 2008. Vol. 29, N 7. P. 1327-1333.
108. Macuuchi R., Terashima M., Kasuhara M. et al. Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach // Biomed. Res. 2017. Vol. 38, N 1. P. 19-27.
109. Maggard M.A., O’Connell J.B., Ko C.Y. Updated population-based review of carcinoid tumors // Ann. Surg. 2004. Vol. 240. P. 117-122.
110. Malanga D., De Gisi S., Riccardi M. et al. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patients with multiple endocrine neoplasia-like phenotype // Eur. J. Endocr. 2012. Vol. 166, N 3. P. 551-560.
111. Mangusto N., Jonson J., Harit A. et al. Prognostic factors associated with outcomes in small bowel neuroendocrine tumors // Am. Surg. 2017. Vol. 83, N 10. P. 1174-1178.
112. Maragliano R., Vanoli A., Albarello L. et al. ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature // Am. J. Surg. Pathol. 2015. Vol. 39, N 3. P. 374-382.
113. Marione I., Kurrer A.S., Vassella E. et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors // Gastroenterology. 2014. Vol. 146, N 2. P. 453-460.
114. McColl C.M., Shi C., Klain A.P. et al. Serotonin expression in pancreatic neuroendocrine tumors correlates with traberular histologic pattern and large duct involvement // Hum. Pathol. 2012. Vol. 43, N 8. P. 1169-1176.
115. Mehrabi A., Fisher L., Hafezi M. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma // Pancreas. 2014. Vol. 43, N 5. P. 875-886.
116. Metz D.C., Cadiot G., Poitras P. et al. Diagnosis of Zollinger-Ellison syndrome in the era PPIs, faulty gastrin assess to acid secretory testing // Int. J. Endocr. Oncol. 2017. Vol. 4, N 4. P. 167-185.
117. Milione M., Maisonnueve P., Spada F. et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories // Neuroendocrinology. 2017. Vol. 104, N 1. P. 85-93.
118. Milione M., Maisonnueve P., Pelligrinelli A. et al. Ki-67 proliferative index of the neuroendocrine component drives MANEC prognosis // Endocr. Ralat. Cancer. 2018. Vol. 25, N 5. P. 583-593.
119. Modlin I.M., Lye K.D., Kidd M.A. 5-decade analysis of 13 715 carcinoid tumors // Cancer. 2003. Vol. 97, N 4. P. 934-959.
120. Mori Y., Sato N., Tanihichi R. et al. Pancreatic somatostatinoma diagnosed preoperatively: report of a case // JOP. 2014. Vol. 15, N 1. P. 66-71.
121. Moris D., Ntanasis-Stathopoulos I., Tsilimigras D.L. et al. Update on surgical management of small bowel neuroendocrine tumors // Anticancer Res. 2018. Vol. 38, N 3. P. 1267-1278.
122. Morris D., Ntansis-Stathopulus I., Tseimigras D.I. et al. Neuroendocrine neoplasms of the appendix: a review of the literature // Anticancer Res. 2018. Vol. 38, N 2. P. 601-611.
123. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances / eds A. Nasir, D. Coppola. Springer, 2016.
124. Norlen O., Stalberg P., Oberg K. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center // World J. Surg. 2012. Vol. 36, N 6. P. 1419-1431.
125. Oberg K. Biological aspects of neuroendocrine gastro-enteropancreatic tumours // Digestion. 1996. Vol. 57, suppl. 10. P. 42-44.
126. Pape U.F., Perren A., Niederle B. et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas // Neuroendocrinology. 2012. Vol. 95. P. 135-156.
127. Papotti M., Cassoni P., Volante M. et al. Ghrelin-producing endocrine tumors of the stomach and intestine // J. Clin. Endocrinol. Metab. 2001. Vol. 86, N 10. P. 5052-5059.
128. Papotti M., Bongiovanni M., Volante M. et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlation immunohistichemical and revers-transcriptase polymerase chain reaction analysis // Virchows Arch. 2002. Vol. 440, N 5. P. 461-475.
129. Park S.Y., Rhee Y., Youn J.C. et al. Ectopic Cushing’s syndrome due concurrent corticotropin-releasing hormone (CRH) and adenocorticotropic hormone (ACTH) secreted by malignant gastrinoma // Exp. Clin. Endocrinol. Diabetes. 2007. Vol. 115, N 1. P. 13-16.
130. Park S.Y., Paik W.H., Lee K. et al. DAXX/ATRX and genes are strong prognostic markers in pancreatic neuroendocrine tumors // Oncotarget. 2017. Vol. 8, N 30. P. 796-806.
131. Pelorsi G., Bresaola E., Bogina G. et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining // Hum. Pathol. 1996. Vol. 27, N 11. P. 1124-1134.
132. Plockinger U., Rindi G., Arnold R. et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European neuroendocrine tumour society (ENETS) // Neuroendocrinology. 2004. Vol. 80. P. 394-424.
133. Raid M.D., Balci S., Saka B. et al. Neuroendocrine tumors of the pancreas: current concepts and controversies // Endocr. Pathol. 2014. Vol. 25, N 1. P. 65-79.
134. Relles D., Baek J., Witkiewicz A. et al. Periampullary and duodenal neoplasms in neurofibromatosis type16 two cases and updated 20-yaer review of the literature yielding 76 cases // J. Gasterointest. Surg. 2010. Vol. 14, N 6. P. 1052-1061.
135. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy // Endocr. Rev. 2003. Vol. 24, N 4. P. 389-427.
136. Rindi G., Bordi C., Rappell S. et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior // Wold J. Surg. 1996. Vol. 20. P. 168-172.
137. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system // Virchows Arch. 2006. Vol. 449. P. 395-401.
138. Rindi G., Kloppel G., Couvelard A. et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system // Virchows Arch. 2007. Vol. 451. P. 757-762.
139. Rindi G., Falconi M., Klersy C. et al. TNM staging of neoplasms of the endocrine pancreas: results a large international cohort study // J. Natl Cancer Inst. 2012. Vol. 104, N 10. P. 764-777.
140. Rindi G., Klersy C., Albarello L. et al. Competitive testing of the 2010 WHO versus the 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study // Neuroendocrinology. 2018. Vol. 107, N 4. P. 375-386.
141. Rindi G., Klimstra D.S., Abedi-Ardekani B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal // Mod. Pathol. 2018. Vol. 31. P. 1770-1786.
142. Rosolen A., Perkins S.L., Pinkerton C.R. et al. Revised international pediatric non-Hodgkin lymphoma staging system // J. Clin. Oncol. 2015. Vol. 33, N 18. P. 2112-2118.
143. Ross-Innes C.S., Becq J., Warren A. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barett’s esophagus and esophageal adenocarcinoma // Nat. Genet. 2015. Vol. 47, N 9. P. 1038-1046.
144. Salazar R., Falconi M., Kaltsas G. et al.; Consensus Conference participants. Rare functioning pancreatic endocrine tumors // Neuroendocrinology. 2006. Vol. 84. P. 189-195.
145. Saqi A., Alexis D., Remotti F. et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids // Am. J. Clin. Pathol. 2005. Vol. 123. P. 394-404.
146. Scardoni M., Vittoria E., Volante M. et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components // Neuroendocrinology. 2014. Vol. 100, N 4. P. 310-316.
147. Scarpa A., Mantovani W., Capelli P. et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients // Mod. Pathol. 2010. Vol. 23, N 6. P. 824-833.
148. Scarpa A., Chang D.K., Nones K. et al. Whole-genome landscape of pancreatic neuroendocrine tumours // Nature. 2017. Vol. 543, N 7643. P. 65-71.
149. Shi C., Klimstra D.S. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics // Semin. Diagn. Pathol. 2014. Vol. 31, N 6. P. 498-511.
150. Schmida H.A., Lambertinib C., van Vugta H.H. et al. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors // Neuroendocrinology. 2012. Vol. 95. P. 232-247.
151. Schmitt A.M., Riniker F., Anlauf M. et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases // Am. J. Surg. Pathol. 2008. Vol. 32, N 3. P. 420-425.
152. Singhara A., Nakasho K., Ikuta S. et al. Oncocytic non-functioning endocrine tumor of the pancreas // Pathol. Int. 2006. Vol. 56, N 12. P. 755-759.
153. Sipos B., Anaulf M. et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations // J. Clin. Endocrinol. Metab. 2015. Vol. 100, N 5. P. E783-E788.
154. Singhi A.D., Klimsrta D.S. Well-differentiated pancreatic neuroendocrine tumours (Pan-NETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concept, issues and practical diagnostic approach to high-grade (G3) cases // Histopathology. 2018. Vol. 72, N 1. P. 168-177.
155. Soga J., Yauwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas // J. Exp. Clin. Cancer Res. 1999. Vol. 18, N 1. P. 13-22.
156. Soga J. Endocrinocarcinoma (carcinoids and their variants) of the duodenum. An evaluation of 927 cases // J. Exp. Clin. Cancer Res. 2003. Vol. 22, N 3. P. 349-363.
157. Song X., Zheng S., Yang G. et al. Glucagonoma and the glucagonoma syndrome // Oncol. Lett. 2018. Vol. 15, N 3. P. 2749-2755.
158. Sorbay H., Welin S., Langer S.W. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study // Ann. Oncol. 2013. Vol. 24, N 1. P. 152-160.
159. Sorbay H., Strosberg J.R., Baudin E. et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma // Cancer. 2014. Vol. 120, N 18. P. 2814-2823.
160. Srivastava A., Fischer-Colbrie R., Padilla O., Dayal Y. Neuroendocrine Secretory Protein 55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids // Am. J. Surg. Pathol. 2004. Vol. 28. P. 1371-1378.
161. Srivastava A., Hornick J.L. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors // Am. J. Surg. Pathol. 2009. Vol. 33. P. 626-632.
162. Strosberg J.R., Coppola D., Klimstra D.S. et al. The NANETS consensus guidelines for the diagnoses and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas // Pencreas. 2010. Vol. 39, N 6. P. 799-800.
163. Vanoli A., La Rosa S., Klersy C. et al. Four neuroendocrine tumor type and neuroendocrine carcinoma of the duodenum: analyses of 203 cases // Neuroendocrinology. 2017. Vol. 104, N 2. P. 112-125.
164. Vanoli A., La Rosa S., Miceli E. et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up // Neuroendocrinology. 2018. Vol. 107, N 2. P. 114-126.
165. Volante M., La Rosa S., Castallano I. et al. Clinico-pathological features of a series of 11 oncocytic endocrine tumors of the pancreas // Virchows Arch. 2006. Vol. 448, N 5. P. 545-551.
166. Volante M., Brizzi M.P., Faggiano A. et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy // Mod. Pathol. 2007. Vol. 20. P. 1172-1182.
167. Volante M., Daniele L., Asioli S. et al. Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix. A retrospective clinical pathologic analysis of 138 cases // Am. J. Surg. Pathol. 2013. Vol. 37. P. 606-612.
168. Volante M., Monica V., Birocco N. et al. Expression analyses of genes involved in DNA repair of synthesis in mixed neuroendocrine/nonneuroendocrine carcinomas // Neuroendocrinology. 2015. Vol. 101, N 2. P. 151-60.
169. Tang L.H., Contractor T., Clausen R. et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased Cdk4/Cdk6 // Clin. Cancer Res. 2012. Vol. 18, N 17. P. 4612-4620.
170. Tang L.H., Basturk O., Sue J.J., Klimstra D.S. Practical approach to the classification of WHO Grade 3(G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas // Am. J. Surg. Pathol. 2016. Vol. 4, N 9. P. 1192-1202.
171. Tanigawa M., Nakayama M., Taira T. et al. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor // Med. Mol. Morphol. 2018. Vol. 51, N 1. P. 32-40.
172. Tseng I.C., Yeh M.M., Yang C.Y., Jeng Y.M. NKX6-1 Is a Novel immunohistochemical marker for pancreatic and duodenal neuroendocrine tumors // Am. J. Surg. Pathol. 2015. Vol. 39, N 6. P. 850-857.
173. Waddell N., Pajic M., Patch A.M. et al. Whole genomes redefine the mutational landscape of pancreatic cancer // Nature. 2015. Vol. 518, N 7540. P. 495-501.
174. World Health Organization Classification of Tumours of Endocrine Organs / eds R. Lloyd, R.Y. Osamura, G. Kloppel., J. Rosai. Lyon : IARC Press, 2017.
175. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System / eds F.T. Bosman, F.T. Carneiro, R.H. Hrubon et al. Lyon : IARC Press, 2010.
176. Yachida S., Vakiani E., White C.M. et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors // Am. J. Surg. Pathol. 2012. Vol. 36, N 2. P. 173-184.
177. Yang Z., Klimstra D.S., Hruban R.H., Tang L.H. Immunohistochemical characterization of the origins of metastatic well-differentiated neuroendocrine tumors to the liver // Am. J. Surg. Pathol. 2017. Vol. 41, N 7. P. 915-922.
178. Yang Z., Tang L.H., Klimstra D.S. et al. Effect of tumor heterogeneity of the assessment of Ki-67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implication for prognostic stratification // Am. J. Surg. Pathol. 2011. Vol. 35, N 6. P. 853-860.
179. Yao J.C., Hassan M., Phatt A. et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States // J. Clin. Oncol. 2008. Vol. 26. P. 3063-3072.
180. Zavras N., Schizas D., Marchairas N. et al. Carcinoid syndrome from a carcinoid tumor of the pancreas without metastases: a case report and literature review // Oncol. Lett. 2017. Vol. 13, N 4. P. 2373-2376.
181. Zhuang B., Xie Q.P., Gao S.L. et al. Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern // J. Zhejiang Univ. Sci. B. 2010. Vol. 11, N 1. P. 22-26.
182. Uccella S., Blank A., Maragliano R. et al. Calcitonin-producing neuroendocrine neoplasms of the pancreas: clinicopathological study of 25 cases and review of the literature // Endocr. Pathol. 2017. Vol. 28, N 4. P. 351-364.